Daihan Pharmaceutical Co.,Ltd.
Financials
Valuation Metrics
Daihan Pharmaceutical Co.,Ltd.'s Market Cap is ₩1584B. At end of 2025 it was ₩1755B. Ranked #997 of 2,421 in KR market (top 41%), #500 of 1,640 on KOSDAQ (top 30%), #112 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 158.40B KRW | KR#997/2,421 Sec#112/231 |
| Revenue | 216.55B KRW | KR#985/2,421 Sec#54/231 |
| Net Income | 27.53B KRW | KR#588/2,421 Sec#35/231 |
| Total Assets | 347.66B KRW | KR#950/2,421 Sec#59/231 |
| Net Assets | 300.21B KRW | KR#715/2,421 Sec#46/231 |
| Employees | 675 | KR#372/2,421 Sec#30/231 |
| Value | ||
| P/E | 5.75x | KR#424/2,421 Sec#16/231 |
| P/B | 0.53x | KR#854/2,421 Sec#41/231 |
| P/S | 0.73x | KR#1,173/2,421 Sec#61/231 |
| EV/EBITDA | 3.80x | KR#131/2,421 Sec#2/231 |
| FCF Yield | 0.30% | KR#1,194/2,421 Sec#89/231 |
| Profitability | ||
| ROE | 9.17% | KR#685/2,421 Sec#46/231 |
| ROA | 7.92% | KR#444/2,421 Sec#34/231 |
| Op. Margin | 13.92% | KR#334/2,421 Sec#32/231 |
| Revenue Growth | 4.27% | KR#1,238/2,421 Sec#122/231 |
| Earnings Growth | -12.12% | KR#888/2,421 Sec#55/231 |
| Financial Health | ||
| Debt Ratio | 15.81% | KR#270/2,421 Sec#40/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 481.5M KRW | KR#1,188/2,421 Sec#91/231 |
| Cash | 43.97B KRW | KR#800/2,421 Sec#50/231 |
| Current Ratio | 3.97x | KR#391/2,421 Sec#59/231 |
| Net Debt/EBITDA | -1.46x | KR#295/2,421 Sec#14/231 |
| Dividend | ||
| Div. Yield | 3.79% | KR#460/2,421 Sec#17/231 |
| Div. Growth | 11.11% | KR#569/2,421 Sec#32/231 |
| Performance | ||
| 1Y Return | -12.58% | KR#1,038/2,421 Sec#68/231 |
| 1M Return | 0.96% | KR#1,120/2,421 Sec#85/231 |
| From 52W High | -16.72% | KR#186/2,421 Sec#7/231 |
| 1Y MDD | -22.20% | KR#87/2,421 Sec#4/231 |
| Trading | ||
| Volume | 1,478 shares | KR#2,296/2,421 Sec#219/231 |
| Trading Value | 38.9M KRW | KR#1,929/2,421 Sec#194/231 |
| Foreign Own. | 20.24% | KR#223/2,421 Sec#10/231 |
| Per Share | ||
| EPS | 4,588 KRW | KR#233/2,421 Sec#14/231 |
| BPS | 50,036 KRW | KR#265/2,421 Sec#17/231 |
Company Info
Established in 1963 and listed on KOSDAQ in 1994, Daehan Pharm is a specialty pharmaceutical company manufacturing and selling infusion solutions. It primarily produces infusion solutions, ampoules, and nutritional solutions for medical facilities, and also enters the pharmacy market with OTC products like contact lens cleaning solutions. The company has established a mass production system and pursues cost reduction through continuous infrastructure development, including automated production lines and warehouses. Daehan Pharm's headquarters are located in Yeongdeungpo-gu, Seoul.